Janice Cowden, MBC Patient Advocate, shared a post on LinkedIn:
“Randomized curative-intent clinical trial for de novo (1st diagnosis, not recurrent MBC) Oligometastatic (1 – 5 metastatic lesions) HER2+ MBC patients within their 1st year since diagnosis and currently on their 1st line of treatment. The trial is currently enrolling at Memorial Sloan Kettering (MSK). Please see description below.
ARCHER Trial – HER2+ Oligometastatic MBC (MSK)
Memorial Sloan Kettering Cancer Center is enrolling patients in the ARCHER trial, a randomized clinical study evaluating whether adding surgery and radiation to standard systemic therapy improves outcomes.
This trial is only for de novo HER2+ oligometastatic metastatic breast cancer, meaning:
- HER2-positive MBC
- Metastatic at first diagnosis
- 5 or fewer metastatic lesions
- Within the first year of first-line treatment
Participants are randomized 1:1 to:
- Standard systemic therapy alone
or - Systemic therapy plus consolidation therapy, including breast surgery and radiation to all metastatic sites
Research components may include blood samples for ctDNA testing, CT/MRI imaging, tissue samples, and patient questionnaires.
Led by Dr. Lior Braunstein at Memorial Sloan Kettering Cancer Center.
ClinicalTrials.gov listing
If you or someone you know may qualify, consider discussing with your oncology team or contacting MSK directly.
See attached photos for more information.”
Other articles featuring Janice Cowden on OncoDaily.
